This article exposes how Group Purchasing Organizations erect invisible barriers that sideline innovative small orthopedic companies, costing patients safer, cheaper solutions—and arms reformers with the facts to dismantle the monopoly.
Picture this: You've sunk years and millions into a cutting-edge orthopedic device—maybe a 3D-printed knee with antimicrobial coatings that slashes infection rates by 20% and costs 30% less than the legacy giants.
Clinical trials? Gold standard.
FDA clearance? Check.
But when you knock on the door of a major hospital system, the response isn't "Show us the data."
It's "Are you on contract with Vizient or Premier?" No?
Then step aside. The train—loaded with Stryker and ZB cargo—barrels past, fueled by multimillion-dollar "admin fees" that small players like you can't afford.
You're left on the platform, ticket in hand, watching innovation get derailed by Group Purchasing Organizations (GPOs) that prioritize volume over value.
This isn't hyperbole; it's the brutal reality of the U.S. ortho medtech ecosystem. As a 30-year veteran who's scouted deals, mentored startups, and dissected this mess on OrthoStreams, I've heard the war stories firstha...
